LONDON The UK is to apply real world evidence to decisions on whether to allow routine commissioning of expensive cancer drugs, providing a fast track to companies that offer lower prices and collect data on patient benefit for the first two years a product is on the market.
During the initial two years when real world effectiveness data are being gathered on how well a product works in practice, drugs will get transitional funding from a Cancer Drugs Fund. If the real world data allow a therapy to pass the cost-effectiveness scrutiny of the health technology assessment body NICE (National Institute for Health and Care Excellence), it will then be routinely commissioned and paid for from the regular National Health Service (NHS) drugs budget.
The proposed scheme is a way of "sorting out the wheat from the chaff," said Simon Stevens, chief executive of NHS England. "Over the next five years we're likely to see many new cancer drugs